Searched for
ARBP
Outlook on healthcare sector; Cipla & Sun Pharma could give 15-20% returnANDA approval rate has been on a steady rise post-COVID, from the low of 540 in CY21 to ~700+ annual approvals in CY23E, backed by a reduct...- Aurobindo Pharma shares jump 7% despite drop in Q4 profits. Should you buy them?Shares of Aurobindo Pharma surged by up to 7.2% to reach Rs 655 in early trade on BSE after receiving favourable views on the stock from se...
- Buy Aurobindo Pharma, target price Rs 900: Motilal OswalAurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 44607.51 Crore) operating in Pharma...
- Buy Aurobindo Pharma, target price Rs 1150: Motilal OswalAurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 57597.77 Crore) operating in Pharma...
- Buy Aurobindo Pharma, target price Rs 1100: Motilal OswalAurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 54796.98 Crore) operating in Pharma...
- Buy Aurobindo Pharma, target price Rs 1030: Motilal OswalAurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 45240.32 Crore) operating in Pharma...
- Buy Aurobindo Pharma, target price Rs 940: Axis SecuritiesAurobindo Pharma Limited (ARBP) manufactures generic pharmaceuticals and active pharmaceuticalingredients.
- Buy Aurobindo Pharma, target price Rs 1055: Motilal OswalAurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 52371.19 Crore) operating in Pharma...
- Buy Aurobindo Pharma, target price Rs 880: Motilal OswalThe brokerage raised the company’s EPS estimate for FY20/FY21 by 4.4 per cent/9 per cent, and expects a 9 per cent earnings CAGR over FY20–...
- Aurobindo Pharma plunges 10% on Sandoz deal termination; what analysts sayCredit Suisse has downgraded the stock to 'underperform' from 'neutral' with a target of Rs 345.
- Buy Aurobindo Pharma, target Rs 860: Reliance SecuritiesAurobindo Pharma (ARBP) is a mid-sized Indian pharma company with one of the largest product portfolios in the US market.
- Buy Aurobindo Pharma, target Rs 920: Phillip Capital (India)Buy Aurobindo Pharma at a price target of Rs 920.
- Buy Aurobindo Pharma, target Rs 836: Elara CapitalBuy Aurobindo Pharma Ltd. at a price target of Rs 836.
- Buy Aurobindo Pharma, target Rs 690: Emkay Global Financial ServicesBuy Aurobindo Pharma Ltd. at a price target of Rs 690.
- Buy Aurobindo Pharma, target Rs 909: Prabhudas LilladherBuy Aurobindo Pharma Ltd. at a price target of Rs 909.0 .
- Buy Aurobindo Pharma, target Rs 740: HDFC SecuritiesBuy Aurobindo Pharma Ltd. at a price target of Rs 740.
- Aurobindo, Intas in race for $1 billion buyout of Teva UK, submit binding offersIf successful, this would be Aurobindo's largest ever acquisition, surpassing its $132.5 mn purchase of US vitamin maker Natrol Inc in 2014.
- Top investment ideas that look good despite weak Q4 results: IndiaNiveshThe fourth-quarter results have been disappointing and the next two do not look promising either according to IndiaNivesh.
- No bubble in midcaps yet, go overweight on large cap stocks; top 10 stocks to bet onThe S&P BSE Small cap index has plunged over 5 per cent so far in the year. The correction since late April has made many stocks attractive.
- Markets to see more pain over short term? Here's what top analysts sayThe BSE Sensex has lost 3.55% so far in 2015. Contrast this with Chinese stocks, which have returned a stunning 52% gains.
Load More
